Publication Author: Basu_Anirban

• Comparative effectiveness of gastric bypass and sleeve gastrectomy on predicted 10-year risk of cardiovascular disease 5 years after surgery.

  Basu A, Barton LJ, Fischer H, Reynolds K, Arterburn DE, Barthold D, Courcoulas A, Crawford CL, Fedorka PN, Kim BB, Mun EC, Murali SB, Zane RE, Coleman KJ. Comparative effectiveness of gastric bypass and sleeve gastrectomy on predicted 10-year risk of card

  rakerr2

  June 1, 2022

• Impact of a statewide Emergency Department Information Exchange on health care use and expenditures.

  Sabbatini AK, McConnell KJ, Parrish C, Frogner BK, Reddy A, Zatzick DF, Kreuter W, Basu A. Impact of a statewide Emergency Department Information Exchange on health care use and expenditures. Health Serv Res. 2022 Jun;57(3):603-613. doi: 10.1111/1475-6773

  rakerr2

  June 1, 2022

• Lifetime medical costs attributable to sickle cell disease among nonelderly individuals with commercial insurance.

  Johnson KM, Jiao B, Ramsey SD, Bender MA, Devine B, Basu A. Lifetime medical costs attributable to sickle cell disease among nonelderly individuals with commercial insurance. Blood Adv. 2022 May 16. pii: bloodadvances.2021006281. doi: 10.1182/bloodadvance

  rakerr2

  May 16, 2022

• Cost-Effectiveness of Remdesivir for COVID-19 Treatment: What Are We Missing?

  Chhatwal J, Basu A. Cost-Effectiveness of Remdesivir for COVID-19 Treatment: What Are We Missing? Value Health. 2022 May;25(5):697-698. doi: 10.1016/j.jval.2022.02.002. Epub 2022 Mar 19.

  rakerr2

  May 1, 2022

• Development of a conceptual model for evaluating new non-curative and curative therapies for sickle cell disease.

  Johnson KM, Jiao B, Bender MA, Ramsey SD, Devine B, Basu A. Development of a conceptual model for evaluating new non-curative and curative therapies for sickle cell disease. PLoS One. 2022 Apr 28;17(4):e0267448. doi: 10.1371/journal.pone.0267448. eCollect

  rakerr2

  April 28, 2022

• Medical and Non-medical Costs of Sickle Cell Disease and Treatments from a US Perspective: A Systematic Review and Landscape Analysis.

  Baldwin Z, Jiao B, Basu A, Roth J, Bender MA, Elsisi Z, Johnson KM, Cousin E, Ramsey SD, Devine B. Medical and Non-medical Costs of Sickle Cell Disease and Treatments from a US Perspective: A Systematic Review and Landscape Analysis. Pharmacoecon Open. 20

  rakerr2

  April 26, 2022

• A landscape analysis and discussion of value of gene therapies for sickle cell disease.

  Quach D, Jiao B, Basu A, Bender MA, Hankins J, Ramsey S, Devine B. A landscape analysis and discussion of value of gene therapies for sickle cell disease. Expert Rev Pharmacoecon Outcomes Res. 2022 Apr 18:1-21. doi: 10.1080/14737167.2022.2060823. [Epub ah

  rakerr2

  April 18, 2022

• Public spending on acute and long-term care for Alzheimer’s disease and related dementias.

  Coe NB, White L, Oney M, Basu A, Larson EB. Public spending on acute and long-term care for Alzheimer’s disease and related dementias. Alzheimers Dement. 2022 Mar 16. doi: 10.1002/alz.12657. [Epub ahead of print]

  rakerr2

  March 16, 2022

• Health State Utilities for Sickle Cell Disease: A Catalog Prepared From a Systematic Review.

  Jiao B, Basu A, Ramsey S, Roth J, Bender MA, Quach D, Devine B. Health State Utilities for Sickle Cell Disease: A Catalog Prepared From a Systematic Review. Value Health. 2022 Feb;25(2):276-287. doi: 10.1016/j.jval.2021.08.002. Epub 2021 Sep 4.

  rakerr2

  February 1, 2022

• Correction to: A sub-group evaluation of the multi-month dispensing strategy for differentiated HIV care: is personalization of care guidelines warranted in Haiti?

  Parrish C, Basu A, Fishman P, Koama JB, Robin E, Francois K, Honoré JG, Van Onacker JD, Puttkammer N. Correction to: A sub-group evaluation of the multi-month dispensing strategy for differentiated HIV care: is personalization of care guidelines warranted

  rakerr2

  January 29, 2022